Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Interim results from the phase 1B and phase 2 TORREY open-label extension study of seralutinib in pulmonary arterial hypertension

Saturday, June 29, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The interim results from the phase 1B and phase 2 TORREY open-label extension study of seralutinib indicate positive outcomes for patients with pulmonary arterial hypertension. The study's comprehensive approach, combining both phases, highlights the potential effectiveness of seralutinib. These findings may pave the way for further developments in treatment options for this condition.
Price reaction · baseline $0.9009 (2024-06-28 close) · hit after-hours · clean, no other GOSS news in the window
day 0 close
+5.2%
day 1
+6.5%
day 3 · peak
+19.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Interim results show promise for seralutinib in treating pulmonary arterial hypertension.
  • The study includes both Phase 1B and Phase 2 data, indicating thorough research.
  • Potential for expanded access for patients with pulmonary arterial hypertension.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Interim results from the phase 1B and phase 2 TORREY open-label extension study of seralutinib in pulmonary arterial hypertension
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is seralutinib used for?

Seralutinib is being investigated for its effectiveness in treating pulmonary arterial hypertension.

What phases are included in the TORREY study?

The TORREY study includes both phase 1B and phase 2 trials.

What are the results of the TORREY study?

The interim results indicate positive outcomes for patients treated with seralutinib.

Is there expanded access for seralutinib?

The study suggests potential for expanded access for patients with pulmonary arterial hypertension.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib pulmonary arterial hypertension TORREY study phase 1B phase 2
Last updated: Jun 29, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →